This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.93% higher to $413.37 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a market capitalization of $105.47 billion, a P/E ratio of -205.81 and a beta of 0.40.

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a ...

ClearBridge Growth Strategy highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ ...